Avid Bioservices Inc (CDMO)

[biopharm]

Development of Surrogate Endpoints for Cancer Immunotherapy Trials

Oct 5, 2014
7 A.M.

This year, in conjunction with the CRI Symposium, we will be hosting a special Cancer Immunotherapy Consortium (CIC) satellite meeting on Sunday, October 5, 2014 entitled Development of Surrogate Endpoints for Cancer Immunotherapy Trials. The meeting will consist of a full day of presentations and panel discussions addressing the key rationale, challenges, and solutions surrounding the development of surrogate endpoints for cancer immunotherapy. This meeting will represent the culmination of a CIC-led community-wide effort that brings together the major stakeholders in the field, including experts from industry, academia, and regulatory bodies as well as patients. The output of the meeting will be a consensus-driven roadmap for the efficient regulatory approval of future immunotherapies.

http://www.cancerresearch.org/grants-programs/cancer-immunotherapy-consortium/annual-scientific-colloquium/2014-satellite-meeting

------------------------------------------------------

leucocytes, white blood cells, circulatory tumor cells, dendritic cells, MDSC's, tumor associated macrophages, ... hell, throw the entire Notch signaling pathway into the mix, because IF Big Pharma wants this advantage, Peregrine gets this advantage. This is where and when all those that relied on fictional, at best sketchy "hmmm, the tumor stopped growing" type of hopium to get an FDA approval are long being dismissed and not even worthy to discuss. Up for discussion? Surrogate endpoints.... : )

Its all about safety, immunotherapy, safe combinations, and raising those criteria that "proves" that the immune system is at its optimal best and Peregrine has it all, in PS Targeting.

------------------------------------------------------------

Whats next ?? I'll leave Bavi crops to the side and all the rest and move on to stroke victims.. Add a little Bavi in some combo, possibly within "Telestroke" for stroke victims?? Hey... blood clots cause flipped-PS and the prior agents ( used with Telestroke) are used after a stroke to "break up" that blood clot, but if Bavi or PS Targeting is the core combo product-- where do you think those PS Targeting agents will go? they will stay with the flipped-PS cells and could that aid in breaking up those blood clots and stopping the irreversible harm that can be fatal just hours after a stroke? .. maybe I should say Bavi 2.0, in case that blood clot is in the brain, where the blood vessels grow narrower and we just may able to get Bavi 1.0/2.0 where ever flipped-PS may exist.

Think Big... Think Bavi 2.0 ...!

Advances in treating strokes expand the time window and allow for remote diagnoses

That’s because strokes, caused by blood clots that cut off circulation to the brain, kill or damage two million brain cells for every minute they’re left untreated.

http://www.miamiherald.com/living/article1981101.html